Hims & Hers Health, Inc. Class A Common Stock (HIMS)
27.39
+0.00 (0.00%)
NYSE· Last Trade: Aug 19th, 8:10 AM EDT
Detailed Quote
Previous Close
27.39
Open
-
Bid
27.11
Ask
27.28
Day's Range
N/A - N/A
52 Week Range
13.74 - 65.30
Volume
73,789
Market Cap
5.26B
PE Ratio (TTM)
53.71
EPS (TTM)
0.5
Dividend & Yield
N/A (N/A)
1 Month Average Volume
14,737,809
Chart
About Hims & Hers Health, Inc. Class A Common Stock (HIMS)
Hims & Hers Health Inc is a telehealth company that focuses on providing accessible and affordable healthcare solutions for a variety of needs, particularly focusing on personal wellness and self-care. The company offers a range of products and services, including prescription medications for conditions such as hair loss, erectile dysfunction, and skincare, as well as wellness supplements and telemedicine consultations. By leveraging technology, Hims & Hers aims to simplify the healthcare experience, making it more convenient for consumers to receive treatment and advice from licensed professionals without the barriers typically associated with traditional healthcare delivery. Read More
Tax withholding drove the disposal of 10,201 shares at $28.15 each, reducing this insider's direct holdings by 5%, though they're still up on a net basis given conversions.
This non-discretionary sale was tied to RSU tax withholding; the insider retains 65,734 direct shares and 428,000 derivative securities, per the filing.
This non-discretionary tax withholding reduced the CTO of Hims' direct holdings, though he retains roughly 194,000 shares and roughly 2 million derivative securities subject to multi-year vesting.
Hims & Hers Health’s second quarter results were driven by strong subscriber growth and a ramp-up in its branded weight loss offerings, yet the market reacte...
Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three ...
The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.
Hims & Hers topped Q2 revenue estimates and raised guidance, but missed EPS forecasts, posted a wider net loss, and faces an FTC lawsuit, leaving Wall Street cautious with a Hold rating.
Telehealth company Hims & Hers Health (NYSE:HIMS) announced better-than-expected revenue in Q2 CY2026, with sales up 38.2% year on year to $753.2 million. On...
Hims & Hers Health (NYSE:HIMS) reported second-quarter 2026 revenue of more than $753 million, up nearly 40% from a year earlier, as the telehealth company added 300,000 net new subscribers and ended the period with nearly 3 million subscribers globally.
Chief Financial Officer Yemi Okupe said dome
Telehealth company Hims & Hers Health (NYSE:HIMS) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 38.2% year on year to $753...
Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading global health and wellness platform, today announced financial results for the second quarter ended June 30, 2026.
